doi: 10.1016/S0140-6736(17)32448-0 23 KuenzigMEFungSGMarderfeldLMakJWYKaplanGGNgSCet al
Huh MS, Ivanochko D, Hashem LE, Curtin M, Delorme M, Goodall E, Yan K, Picketts DJ (2016) Stalled replication forks within heterochromatin require ATRX for protection
Schedule Your Free Consultation to Claim 20% Off Your First Treatment New Clients Only Why Choose Newest Beginnings for Your Guided Weight Loss Journey Licensed Medical Providers on Staff Our board-certified professionals prescribe and monitor all treatmentsensuring a safe and medically sound approach to your goals
499 Kuo, H.-L
A significant number of patients with multiple myeloma continue to relapse and become refractory to currently available therapies, representing one of the largest and most challenging unmet needs in the disease, Ester in t Groen, EMEA Therapeutic Area head, Haematology, at Johnson & Johnson, stated in a news release.1 Making teclistamab monotherapy available to patients as early as second line, where it has the potential to meaningfully improve long-term outcomes and change the course of the disease, could bring new hope to patients and their families. To view or add a comment, sign in 7,047 followers
Tirzepatide Titration: typically starts at 2.5mg, then 5mg, 7.5mg, up to 15mg weekly
